Botulinum toxin type B: A new injectable treatment for cervical dystonia

Research output: Contribution to journalArticle

12 Scopus citations

Abstract

Cervical dystonia (CD) causes involuntary muscle spasms and is often associated with pain. Recently, botulinum toxin type B (BTX-B) (Myobloc™, Elan South San Francisco, CA, USA) was approved for general use in the treatment of CD in the USA. In two large pivotal trials, BTX-B was found to be safe and effective in decreasing the movements, pain and disability associated with CD. Benefits were noted both in patients who no longer respond and in those who continue to respond to botulinum toxin type A (BTX-A). BTX-B offers an additional therapeutic option for patients with CD.

Original languageEnglish (US)
Pages (from-to)2191-2199
Number of pages9
JournalExpert Opinion on Investigational Drugs
Volume10
Issue number12
DOIs
StatePublished - Dec 31 2001
Externally publishedYes

Keywords

  • Botulinum toxin
  • Cervical dystonia
  • Chemodenervation
  • Myobloc™
  • NeuroBloc®

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Botulinum toxin type B: A new injectable treatment for cervical dystonia'. Together they form a unique fingerprint.

  • Cite this